Tirzepatide

FDA Approved

Also known as: Mounjaro, Zepbound

Track with CalcPep

What is Tirzepatide?

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes and chronic weight management.

How It Works

Tirzepatide activates both GIP and GLP-1 receptors, providing enhanced glycemic control and weight loss compared to GLP-1 agonists alone.

What Research Shows

50
Animal Studies
30
Human Studies

Key Findings:

  • Up to 22.5% body weight loss in trials
  • Superior A1C reduction vs semaglutide
  • Improved cardiometabolic markers

Dosing Protocol

Typical Dose
2.5-15 mg
Frequency
Once weekly
Route
Subcutaneous injection
Duration
Ongoing

These are general guidelines based on research literature and community protocols. Individual dosing should be determined by a qualified healthcare provider.

Safety & Risks

Reported Side Effects:

NauseaDiarrheaDecreased appetiteVomitingConstipation

Contraindications:

  • Personal/family history of medullary thyroid carcinoma
  • MEN 2 syndrome
  • Pregnancy

Important: This information is for research purposes only. Always consult with a qualified healthcare provider before using any peptide. Never use peptides without proper medical supervision.

Sourcing & Quality

Quality varies significantly between peptide sources. When sourcing Tirzepatide, consider:

  • Third-party testing (HPLC, Mass Spectrometry)
  • Certificate of Analysis (CoA) availability
  • Purity levels (>98% recommended)
  • Beware of LPS (endotoxin) contamination

CalcPep does not sell peptides or recommend specific vendors. Always verify product quality through independent testing.

Frequently Asked Questions

Quick Facts
Category
Weight Loss
Status
FDA Approved
Typical Dose
2.5-15 mg
Route
Subcutaneous injection
Duration
Ongoing
Real-World Data
3,891
Users Reporting

Aggregated from CalcPep users who have opted in to share anonymous data.

View Full Data

Track Your Protocol

Use CalcPep to calculate doses, log injections, and track your progress.

Get CalcPep